PrIMAVeRa – Estimating antimicrobial resistance burden in Europe: what are the next steps?

Abstract: No abstract

Authors: Hassoun-Kheir, N., Harbarth, S.

Source: The Lancet, Public Health

DOI:https://doi.org/10.1016/S2468-2667(22)00250-X

You might also like
COMBINE – Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections
PrIMAVeRa – Frequency of bloodstream infections caused by six key antibiotic-resistant pathogens for prioritization of research and discovery of new therapies in Europe: a systematic review
COMBINE – Challenges for Clinical Development of Vaccines for Prevention of Hospital-Acquired Bacterial Infections
PrIMAVeRa – Targeted mupirocin-based decolonization for Staphylococcus aureus carriers and the subsequent risk of mupirocin resistance in haemodialysis patients: a longitudinal study over 20 years
PrIMAVeRa – Synthesizing pathogen- and infection-specific estimates of the burden of antimicrobial resistance in Europe for health-technology assessment: gaps, heterogeneity, and bias
PrIMAVeRa – A systematic review on the excess health risk of antibiotic-resistant bloodstream infections for six key pathogens in Europe